NCT03941769View on ClinicalTrials.gov

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions
Acute Myeloid LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveCord Blood Transplant RecipientMyelodysplastic SyndromeMyeloproliferative Neoplasm
Interventions
BIOLOGICAL

Recombinant Interleukin-7

Given IM or SC

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03941769 - 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | Biotech Hunter | Biotech Hunter